Bumper investment in gene therapists Vivet Therapeutics

4 May 2017

The venture capital arms of Swiss giants Novartis (NOVN: VX) and Roche (ROG: SIX) have invested heavily in a French biotech startup called Vivet Therapeutics.

The company managed to attract 37.5 million euros' ($41 million) worth of interest from a diverse range of investors, in order to fund pre-clinical development of its gene therapy pipeline.

Vivet, which is focused on developing treatments for rare inherited metabolic diseases, is using a technology licensed from the non-profit group Fundación para la Investigación Médica Aplicada (FIMA), associated with the University of Navarra, Spain.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK